Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06104319
PHASE2

Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH

Sponsor: GlaxoSmithKline

View on ClinicalTrials.gov

Summary

The purpose of this study is to understand how the drug GSK4532990 is processed in the body (pharmacokinetics) and how it works in the liver (pharmacodynamics) as well as to ensure it is safe and well-tolerated. The total study duration for each participant will be approximately 24-36 weeks.

Official title: A Phase 2a, Single Dose, Open-label, Dose Exploration Study to Assess the PK-PD Activity, Safety, and Tolerability of GSK4532990 in Adult. Participants With NASH or Suspected NASH

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

61

Start Date

2024-01-22

Completion Date

2025-09-23

Last Updated

2026-10-27

Healthy Volunteers

No

Interventions

DRUG

GSK4532990

GSK4532990 will be administered

Locations (14)

GSK Investigational Site

Chula Vista, California, United States

GSK Investigational Site

Montclair, California, United States

GSK Investigational Site

San Diego, California, United States

GSK Investigational Site

San Diego, California, United States

GSK Investigational Site

Brandon, Florida, United States

GSK Investigational Site

Miami, Florida, United States

GSK Investigational Site

Miami, Florida, United States

GSK Investigational Site

Miami Lakes, Florida, United States

GSK Investigational Site

Indianapolis, Indiana, United States

GSK Investigational Site

El Dorado, Kansas, United States

GSK Investigational Site

Marrero, Louisiana, United States

GSK Investigational Site

Austin, Texas, United States

GSK Investigational Site

San Antonio, Texas, United States

GSK Investigational Site

San Antonio, Texas, United States